Bausch + Lomb's Valuation: A Look at Q3 Earnings and Upgraded Guidance

Bausch + Lomb reported Q3 2025 earnings and revenue that beat expectations, with growth across its business segments and upgraded full-year guidance. The company's shares have surged 13.5% in the past 90 days, but its 1-year total shareholder return remains in negative territory. With a price-to-sales ratio of 1.1x, significantly lower than its peers and the US Medical Equipment industry, Bausch + Lomb may be undervalued, with potential upside if investor sentiment shifts or the business executes on its growth outlook.